LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.83 -2.82

Buy Sell

Overview

Share price change

24h

Current

Min

4.7

Max

5.41

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+203.4% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	-26M 229M
Previous open	7.65
Previous close	4.83

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2026, 19:18 UTC

Major Market Movers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Market Talk

Major News Events

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Major News Events

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Major News Events

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Earnings

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Earnings

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Earnings

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Acquisitions, Mergers, Takeovers

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Earnings

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Major News Events

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Earnings

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Major News Events

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Market Talk

Major News Events

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Acquisitions, Mergers, Takeovers

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Major News Events

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

203.4% upside

12 Months Forecast

Average 15.17 USD 203.4%

High 25 USD

Low 10 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.